Today, we’re talking about state-level legislation concerning the substitution of interchangeable biosimilars, and how 1 specific piece of biosimilars-focused legislation led Marcus Snow, MD, to found the Nebraska Rheumatology Society.
Subscribe to "Not So Different" on iTunes.
Last time on the podcast, we spoke with Christine Simmon of the Biosimilars Council about how the CREATES Act, a piece of legislation before Congress, could impact biosimilars. Today, we’re talking about state-level legislation concerning the substitution of interchangeable biosimilars, and how 1 specific piece of biosimilars-focused legislation led to the formation of the Nebraska Rheumatology Society.
Our guest this week is Marcus Snow, MD, a rheumatologist at the University of Nebraska Medical Center, and assistant professor of rheumatology at the University of Nebraska. Dr Snow joined The Center for Biosimilars® by phone to tell me how the Nebraska Rheumatology Society came to be.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilars Policy Roundup for March 2023—Podcast Edition
April 2nd 2023On this episode of Not So Different, we discuss some of the global biosimilar policy news that came out during the month of March, including a new bill in Congress and 2 Canadian jurisdictions implementing switching policies.
Biosimilars Gastroenterology Roundup for February 2023—Podcast Edition
March 5th 2023On this episode of Not So Different, we chronicle the latest gastroenterology news from February, including several updates on adalimumab and infliximab biosimilars and industry analyses on the utilization of these drugs and patient confidence in gastroenterologists’ recommendations.